Literature DB >> 26548401

IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review).

Xinxin Long1, Yingnan Ye2, Lijie Zhang1, Pengpeng Liu2, Wenwen Yu1, Feng Wei1, Xiubao Ren1, Jinpu Yu1.   

Abstract

The epithelial-mesenchymal transition (EMT) is a process through which epithelial cells trans-differentiate and acquire an aggressive mesenchymal phenotype. In tumor cells, EMT is a vital step of tumor progression and metastasis. Amid the increasing interest in tumor EMT, only a few studies focused on the soluble mediators secreted by tumor cells passing through this phenotypic switch. In this review, we focus on the essential role of interleukin-8 (IL-8) signaling for the acquisition and maintenance of tumor EMT via direct and indirect mechanisms. Besides the autocrine loop between IL-8 and tumor cells that have gone through EMT, IL-8 could potentiate adjacent epithelial tumor cells into a mesenchymal phenotype via a paracrine mode. Moreover, understanding the role of IL-8 in EMT will provide insight into the pathogenesis of tumor progression and may facilitate the development of an effective strategy for the prevention and treatment of metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26548401     DOI: 10.3892/ijo.2015.3234

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  45 in total

1.  Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis.

Authors:  Kelly E Johnson; Julia R Ceglowski; Harvey G Roweth; Jodi A Forward; Mason D Tippy; Saleh El-Husayni; Rajesh Kulenthirarajan; Michael W Malloy; Kellie R Machlus; Wendy Y Chen; Joseph E Italiano; Elisabeth M Battinelli
Journal:  Blood Adv       Date:  2019-01-22

2.  ERK3/MAPK6 controls IL-8 production and chemotaxis.

Authors:  Katarzyna Bogucka; Malvika Pompaiah; Federico Marini; Harald Binder; Gregory Harms; Manuel Kaulich; Matthias Klein; Christian Michel; Markus P Radsak; Sebastian Rosigkeit; Peter Grimminger; Hansjörg Schild; Krishnaraj Rajalingam
Journal:  Elife       Date:  2020-04-21       Impact factor: 8.140

Review 3.  Insulin Resistance and Urolithiasis as a Challenge for a Dietitian.

Authors:  Michalina Lubawy; Dorota Formanowicz
Journal:  Int J Environ Res Public Health       Date:  2022-06-10       Impact factor: 4.614

Review 4.  Regulation of CTNNB1 signaling in gastric cancer and stem cells.

Authors:  Shihori Tanabe; Kazuhiko Aoyagi; Hiroshi Yokozaki; Hiroki Sasaki
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

Review 5.  Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity.

Authors:  Sugandha Saxena; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

Review 6.  Interleukins in cancer: from biology to therapy.

Authors:  Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold
Journal:  Nat Rev Cancer       Date:  2021-06-03       Impact factor: 69.800

Review 7.  Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells.

Authors:  Shayda Hemmati; Tamanna Haque; Kira Gritsman
Journal:  Front Oncol       Date:  2017-11-13       Impact factor: 6.244

Review 8.  New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer.

Authors:  Munazza Ahmed; Grace Hope Daoud; Asmaa Mohamed; Rania Harati
Journal:  Genes (Basel)       Date:  2021-05-12       Impact factor: 4.096

Review 9.  The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance.

Authors:  Justin M David; Charli Dominguez; Duane H Hamilton; Claudia Palena
Journal:  Vaccines (Basel)       Date:  2016-06-24

10.  Lung epithelial-specific TRIP-1 overexpression maintains epithelial integrity during hyperoxia exposure.

Authors:  Michael F Nyp; Sherry M Mabry; Angels Navarro; Heather Menden; Ricardo E Perez; Venkatesh Sampath; Ikechukwu I Ekekezie
Journal:  Physiol Rep       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.